AbbVie reported strong financial performance and growth across several key segments, with significant contributions from Skyrizi, Rinvoq, and the neuroscience portfolio. However, challenges persist in the aesthetics segment and HUMIRA's decline due to biosimilar competition. Overall, the highlights, including raised guidance and pipeline advancements, outweigh the lowlights.

Company Guidance -

Q3 2025

During AbbVie's Second Quarter 2025 Earnings Conference Call, the company reported robust financial performance, surpassing expectations. AbbVie achieved adjusted earnings per share of $2.97, which was $0.11 above the guidance midpoint, and total net revenues of $15.4 billion, exceeding expectations by over $400 million. The company's ex-HUMIRA platform sales grew by 22%, with Skyrizi and Rinvoq projected to generate more than $25 billion in combined sales this year. Neuroscience also displayed double-digit growth, driven by Vraylar, Vyalev, and a leading migraine portfolio. Due to this momentum, AbbVie raised its full-year revenue guidance to $60.5 billion, marking an $800 million increase, and adjusted earnings per share guidance to a range of $11.88 to $12.08. Furthermore, the company highlighted significant progress in its R&D pipeline, including approvals and submissions for late-stage programs, and emphasized its strategic business development activities, having executed over 30 transactions since last year to strengthen its long-term growth prospects.

Record-Breaking Revenue and Growth

AbbVie delivered adjusted earnings per share of $2.97, which is $0.11 above guidance. Total net revenues were $15.4 billion, exceeding expectations by more than $400 million. The company raised full year revenue guidance by $1.5 billion since the start of the year.

Strong Performance from Ex-HUMIRA Platform

Sales growth of 22% from the ex-HUMIRA platform, driven by Skyrizi and Rinvoq, with a combined sales target of over $25 billion for the year. Skyrizi's global sales were $4.4 billion, up 61.8%, and Rinvoq's sales were $2 billion, up 41.2%.

Neuroscience Segment Growth

Neuroscience total revenues were approximately $2.7 billion, up 24%. Vraylar's sales were $900 million, up 16.3%, and QULIPTA's sales were $267 million, up 76.9%.

Advancements in R&D Pipeline

FDA approval of Rinvoq for GCA and positive Phase III results in alopecia areata. The company announced a deal with Capstan Therapeutics for an in vivo CAR-T platform.

AbbVie (DE:4AB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:4AB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	2.86 / -	2.63	―	―	―
Jul 31, 2025	2025 (Q2)	2.52 / 2.60	2.323	12.08% (+0.28)	―
Apr 25, 2025	2025 (Q1)	2.09 / 2.16	2.025	6.49% (+0.13)	―
Jan 31, 2025	2024 (Q4)	1.85 / 1.89	2.446	-22.58% (-0.55)	―
Oct 30, 2024	2024 (Q3)	2.56 / 2.63	2.586	1.69% (+0.04)	―
Jul 25, 2024	2024 (Q2)	2.25 / 2.32	2.551	-8.93% (-0.23)	―
Apr 26, 2024	2024 (Q1)	1.98 / 2.02	2.156	-6.10% (-0.13)	―
Feb 02, 2024	2023 (Q4)	2.45 / 2.45	3.156	-22.50% (-0.71)
Oct 27, 2023	2023 (Q3)	2.51 / 2.59	3.208	-19.40% (-0.62)	―
Jul 27, 2023	2023 (Q2)	2.48 / 2.55	2.954	-13.65% (-0.40)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:4AB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	€166.20	€170.00	+2.29%
Apr 25, 2025	€157.03	€159.81	+1.77%
Jan 31, 2025	€165.61	€177.59	+7.24%
Oct 30, 2024	€170.81	€177.76	+4.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.